IGF-1 LR3

What Is IGF‑1 LR3?

IGF‑1 LR3 (Insulin‑Like Growth Factor‑1 Long Arg3) is a recombinant synthetic analog of human IGF‑1, modified with a substitution of arginine at position 3 and an extended N‑terminal sequence. These structural changes significantly reduce binding affinity to IGF‑binding proteins (IGFBPs), thereby prolonging biological half‑life and enhancing systemic bioavailability. IGF‑1 LR3 has been studied in preclinical and investigational contexts for its anabolic, regenerative, and metabolic properties.

Mechanism of Action

IGF‑1 LR3 binds to IGF‑1 receptors (IGF‑1R) and insulin receptors, activating downstream PI3K/Akt and MAPK signaling cascades. This receptor engagement promotes protein synthesis, cell proliferation, and differentiation, while inhibiting apoptosis. The modification reduces sequestration by IGFBPs, allowing greater receptor activation and sustained activity. As a result, IGF‑1 LR3 supports muscle hypertrophy, tissue repair, and metabolic regulation. Its pleiotropic effects extend to neuroprotection, angiogenesis, and glucose metabolism, making it a candidate for regenerative and performance research.

Research & Clinical Data

IGF‑1 LR3 remains investigational, with limited human clinical trial data. Preclinical studies suggest benefits in muscle growth, recovery from injury, and metabolic enhancement. It has been explored in contexts such as age‑related decline, cachexia, and regenerative medicine. Regulatory approval for therapeutic use has not been established, and its application remains restricted to research environments.

Purity & Quality

Reference‑grade peptide material. Certificate of Analysis available per batch. Regulatory status: investigational, not FDA‑ or EMA‑approved.

Classification & Handling Class: Recombinant IGF‑1 analog | Modification: Long Arg3 substitution | Administration: Subcutaneous injection | Storage: 2–8°C refrigerated, protect from light | Regulatory: Investigational, non‑approved